Moderna Therapeutics today reported a 94.5% efficacy for its COVID-19 vaccine, which needn't be stored at the same ultra-cold temperatures as does a similar vaccine developed by Pfizer. It also said short-term safety concerns, such as headaches and injection site soreness, self-resolved within days, and that it could have 20 million doses available by year-e ... Show More
Dec 2021
The year psychedelics went mainstream
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022. Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major ... Show More
11m 21s
Dec 2021
Is Pfizer's antiviral pill the game changer we've been waiting for? Plus, is it still accurate to call this a pandemic of the unvaccinated?
Promising data from Pfizer shows its antiviral Covid-19 pill reduces severe illness, hospitalizations, and death. And it appears to hold up against the Omicron variant.A healthcare professional who is fully vaccinated and boosted just came down with Covid-19 for a second time.Cal ... Show More
24m 20s
Jun 2021
Covipod #9 : Le vaccin, moins efficace chez certaines personnes
Aujourd'hui, dans Covipod, nous nous penchons sur le cas des personnes que les deux doses de vaccin ne suffisent pas à protéger contre la Covid-19, et sur les mesures à prendre pour s'assurer qu'elles n'attrapent pas la maladie. Nous ferons ensuite un bref état des lieux autour d ... Show More
5m 43s